Maybe JAV will acquire MDCO. Only semi-kidding...if Dyloject and ketamine are successful, and MDCO has any delays for Cleviprex and cangrelor, JAV's market cap will easily exceed that of MDCO.
More realistically, though, I'd like to see MDCO buy JAV. They have some truly spectacular marketers at MDCO; if they acquired JAV's products and kept top management on I would consider buying MDCO.
Too bad their lawyers aren't equally good. Damn shame that Angiomax problem.
And I underestimated MDCO's market cap pre-tragedy. In January, it was about $1.6 billion. Essentially on Angiomax alone. Bodes well for JAV.
News 
Market Data 
Discover 
AI
